Poor
Major Misalignment
Patient Risk:
Moderate
Summary
Partially matches label-supported mechanism and muscle adverse-event concepts, but includes multiple claims about discontinuation causing cholesterol rebound, “withdrawal” symptoms, and increased CV risks that are not supported by the provided label excerpts/citations.
Category Scores
Accurate Statements
Lipitor (atorvastatin) lowers LDL cholesterol in the blood.
Supported by 12.1 Mechanism of Action.
Lipitor works by inhibiting the enzyme HMG-CoA reductase.
Supported by 12.1 Mechanism of Action.
Statins like Lipitor can cause muscle pain and weakness.
Supported by 5.1 Skeletal Muscle.
Rhabdomyolysis can lead to kidney failure.
Supported by 5.1 Skeletal Muscle (rhabdomyolysis with acute renal failure secondary to myoglobinuria).
Unsupported Statements
By reducing cholesterol production, Lipitor helps lower the risk of heart disease and stroke.
Only partially supported: mechanism and CV risk reduction are present (12.1, 1.1), but the phrasing is broad and not specifically tied to the claim as stated.
Stopping Lipitor may cause cholesterol levels to increase.
Not supported by the provided label excerpts/citations.
Increased cholesterol levels after stopping Lipitor can increase the risk of heart disease.
Not supported by the provided label excerpts/citations.
Increased cholesterol levels after stopping Lipitor can increase the risk of stroke.
Not supported by the provided label excerpts/citations.
Stopping a statin like Lipitor may cause cholesterol levels to rebound.
Not supported by the provided label excerpts/citations.
Stopping Lipitor may increase the risk of cardiovascular events.
Not supported by the provided label excerpts/citations.
Stopping Lipitor can lead to rhabdomyolysis.
While rhabdomyolysis is described as a rare adverse event, the specific causal claim that it happens due to stopping is not supported by the provided label excerpts/citations.
Rhabdomyolysis can cause muscle damage.
Not supported by the provided label excerpts/citations.
Lipitor can cause liver damage.
Only partially supported: the label discusses liver enzyme abnormalities and monitoring; the claim is broad ('liver damage') beyond provided excerpt wording.
Stopping Lipitor can lead to liver failure.
Not supported by the provided label excerpts/citations.
Stopping Lipitor can increase the risk of heart attack.
Not supported as a discontinuation risk statement in the provided excerpts/citations (1.1 addresses indicated risk reduction during use).
Stopping Lipitor can increase the risk of stroke.
Not supported as a discontinuation risk statement in the provided excerpts/citations (1.1 addresses indicated risk reduction during use).
Some people may experience withdrawal symptoms when stopping Lipitor.
Not supported by the provided label excerpts/citations.
Withdrawal symptoms after stopping Lipitor can include headaches.
Not supported by the provided label excerpts/citations.
Withdrawal symptoms after stopping Lipitor can include fatigue.
Not supported by the provided label excerpts/citations.
Withdrawal symptoms after stopping Lipitor can include muscle pain.
Not supported by the provided label excerpts/citations.
Withdrawal symptoms after stopping Lipitor are usually mild.
Not supported by the provided label excerpts/citations.
Withdrawal symptoms after stopping Lipitor are usually temporary.
Not supported by the provided label excerpts/citations.
Some people should talk to a doctor before stopping Lipitor.
Not supported by the provided label excerpts/citations (general counseling provided does not mention 'withdrawal symptoms' or stopping advice in the provided data).
A doctor may recommend gradually reducing the dose of Lipitor to minimize the risk of withdrawal symptoms.
Not supported by the provided label excerpts/citations.
Cholesterol levels should be monitored regularly after stopping Lipitor to ensure they do not increase.
Not supported by the provided label excerpts/citations (label mentions periodic testing of fasting lipid panel for adherence/goal attainment while on therapy; discontinuation-specific monitoring after stopping is not provided in the excerpted material).
If experiencing side effects or other issues with Lipitor, a doctor may recommend alternative medications or treatments.
Not supported by the provided label excerpts/citations.
Contradictions
Important Omissions
Key labeled safety content is not represented in the provided claims/extracted set (e.g., contraindications, boxed warnings, detailed liver monitoring approach, and specific discontinuation/withholding instructions tied to myopathy risk).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple discontinuation/“withdrawal” and increased CV risk claims are not supported by the provided label excerpts/citations, which could misinform treatment decisions or expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Major Misalignment
Primary Issue
Discontinuation-related claims (cholesterol rebound, “withdrawal symptoms,” and increased CV outcomes after stopping) are not supported by the provided prescribing information excerpts/citations.
Suggested Improvement
Restrict statements to label-supported content from the provided sections (e.g., mechanism of HMG-CoA reductase inhibition; labeled muscle adverse event/rhabdomyolysis description; liver enzyme abnormality monitoring) and remove or rephrase any stopping/withdrawal/rebound/discontinuation risk statements that are not explicitly supported in the provided label excerpts.